Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

24

Revenue 2017

Daiichi Sankyo

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Daiichi Sankyo's 2012 sales performance.

Daiichi Sankyo

Roche preps new Kadcyla filings after phase 3 trial win

Roche preps new Kadcyla filings after phase 3 trial win

Meanwhile, moving Kadcyla up the treatment pathway should help keep the ADC – currently the smallest product of the three – ahead of emerging rivals, such as  Daiichi-Sankyo’s ADC trastuzumab deruxtecan

Daiichi-Sankyo takes rival to Roche’s Kadcyla into phase 3

Daiichi-Sankyo takes rival to Roche’s Kadcyla into phase 3 Daiichi-Sankyo takes rival to Roche’ s Kadcyla into phase 3. Contender could offer potency without dose-limiting toxicities. ... If successful in phase 3, Daiichi-Sankyo’s drug could muscle into Kadcyla’s territory and provide another line of HER2

Cello Health poaches Astellas' comms chief, Ketchum hires healthcare comms specialist and Uptake Strategies expand team

Cello Health poaches Astellas' comms chief, Ketchum hires healthcare comms specialist and Uptake Strategies expand team She has also served in various positions for Daiichi Sankyo, Novartis, Eli Lilly and GlaxoSmithKline.

Vernalis accepts £33m takeover offer from Ligand Pharma

Vernalis accepts £33m takeover offer from Ligand Pharma If the deal goes through, Ligand will inherit a portfolio of more than eight fully-funded partnered programmes focused around central nervous system, oncology and inflammation, including collaborations with Servier, Daiichi ... Sankyo, Lundbeck, Asahi

Result pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 ()

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics